Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Gimsing

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Cytometry. Part B, Clinical Cytometry|June 10, 2010
Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myelomaHans E Johnsen, Martin Bøgsted, Tobias W Klausen, et al.
Haematologica|July 29, 2017
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone <i>vs</i>. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1María-Victoria Mateos, Tamas Masszi, Norbert Grzasko, et al.
Haematologica|September 8, 2006
Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantationStig Lenhoff, Martin Hjorth, Ingemar Turesson, et al.
Cancer Medicine|April 20, 2018
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myelomaJohan Lund, Astrid Gruber, Birgitta Lauri, et al.
European Journal of Haematology|March 13, 2012
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized studyMartin Hjorth, Øyvind Hjertner, Lene Meldgaard Knudsen, et al.
The Lancet. Oncology|September 25, 2010
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trialPeter Gimsing, Kristina Carlson, Ingemar Turesson, et al.
Blood|August 18, 2016
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myelomaTorben Plesner, Hendrik-Tobias Arkenau, Peter Gimsing, et al.
The New England Journal of Medicine|August 27, 2015
Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaHenk M Lokhorst, Torben Plesner, Jacob P Laubach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2021
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaPaul G Richardson, Shaji K Kumar, Tamás Masszi, et al.
Blood|April 26, 2013
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trialUlf-Henrik Mellqvist, Peter Gimsing, Oyvind Hjertner, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Cytometry. Part B, Clinical Cytometry|June 10, 2010
Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myelomaHans E Johnsen, Martin Bøgsted, Tobias W Klausen, et al.
Haematologica|July 29, 2017
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone <i>vs</i>. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1María-Victoria Mateos, Tamas Masszi, Norbert Grzasko, et al.
Haematologica|September 8, 2006
Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantationStig Lenhoff, Martin Hjorth, Ingemar Turesson, et al.
Cancer Medicine|April 20, 2018
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myelomaJohan Lund, Astrid Gruber, Birgitta Lauri, et al.
European Journal of Haematology|March 13, 2012
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized studyMartin Hjorth, Øyvind Hjertner, Lene Meldgaard Knudsen, et al.
The Lancet. Oncology|September 25, 2010
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trialPeter Gimsing, Kristina Carlson, Ingemar Turesson, et al.
Blood|August 18, 2016
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myelomaTorben Plesner, Hendrik-Tobias Arkenau, Peter Gimsing, et al.
The New England Journal of Medicine|August 27, 2015
Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaHenk M Lokhorst, Torben Plesner, Jacob P Laubach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2021
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaPaul G Richardson, Shaji K Kumar, Tamás Masszi, et al.
Blood|April 26, 2013
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trialUlf-Henrik Mellqvist, Peter Gimsing, Oyvind Hjertner, et al.
Pageof 6